|
Delayed
Nasdaq Stockholm
04:45:43 15/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1.896 SEK | +0.42% |
|
+4.18% | -3.76% |
| 03/09 | Irlab CEO Kristina Torfgaard to step down in 2027 | FW |
| 03/09 | Irlab CEO Kristina Torfgaard wants to step down | FW |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 280.8 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | 67.8% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 280.8 | 280.8 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | 67.8% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 2.77x | 1.96x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.77x | 1.96x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -9.89x | 7.27x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -8.94x | 8.11x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 101.2 | 143.2 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -28.4 | 38.6 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.4 | 34.6 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -36.1 | 34.6 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.000 | 38.300 | 7.500 | 10.750 | 1.970 | 1.888 | 1.888 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 1,48,712 | - |
| Announcement Date | 23/02/22 | 23/02/23 | 07/02/24 | 12/02/25 | 25/02/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 2.79Cr | |
| 34.58x | 12.46x | 26.12x | 0.57% | 1,07700Cr | |
| 37.53x | 6.26x | 17.55x | 2.1% | 61TCr | |
| 36.12x | 8.31x | 17.13x | 2.45% | 50TCr | |
| 113.84x | 6x | 25.7x | 2.32% | 36TCr | |
| 20.01x | 4.88x | 12.13x | 2.7% | 35TCr | |
| 20.46x | 5.37x | 13.21x | 2.96% | 28TCr | |
| 21.15x | 4.27x | 12.26x | 2.07% | 25TCr | |
| 27.06x | 6.97x | 12.48x | 2.37% | 23TCr | |
| -44.86x | 6.85x | 26.64x | 2.14% | 19TCr | |
| Average | 29.54x | 6.82x | 18.14x | 2.19% | 38.57TCr | |
| Weighted average by Cap. | 35.12x | 7.99x | 19.65x | 1.87% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
